Oragenics, Inc.

What they do

Oragenics is developing nasally delivered pharmaceutical therapies for neurological conditions using a proprietary breath-propelled intranasal device. Its lead candidate, ONP-002, is a fully synthetic, non-naturally occurring lipophilic neurosteroid intended to cross the blood-brain barrier to reduce swelling, oxidative stress and inflammation. The company's stated lead focus is mild traumatic brain injury (concussion). It is a development-stage company and does not currently generate meaningful product revenue.

Revenue drivers

• ONP-002 (mTBI/concussion) — Lead product candidate; the company reports no product revenue from it and is still in clinical development. It is the central asset of the business and any future revenue would depend on successful trials and regulatory approval.
• Other Neurology Assets — ONP-002 is grouped with other neurology assets referred to as the Neurology Assets; the excerpts provide no separate revenue or stage detail for these beyond ONP-002.
• Nasal delivery device — A proprietary breath-propelled intranasal device used to administer ONP-002; the company describes it as novel and lightweight but reports no device revenue.
• Historical revenue (immaterial) — Reported annual revenue was $86,987 in 2021, $131,521 in 2022 and $37,653 in 2023, and $0 in 2016-2017; revenue is not a current source of operating funding.

Recent performance

The company reported quarterly revenue of $17,024 (Q1 2023), $13,163 (Q2 2023), $7,466 (Q3 2023) and $0 (Q4 2023), showing no recurring revenue stream. Annual net losses were $15.7M (2021), $14.3M (2022), $20.7M (2023), $1.06B (2024) and $984.2M (2025) as reported. Operating cash flow was negative each year, including -$8.6M in 2024 and -$9.2M in 2025. As of June 30, 2026, the company reported total assets of $5.5M, total liabilities of $1.8M, shareholder equity of $3.7M and cash and equivalents of $3.9M. As of June 30, 2026, the 10-Q states the company had enrolled 9 participants in its ongoing study.

Strategy

Management states the priority is advancing development and commercialization of ONP-002 for mild traumatic brain injury. The 10-K lists a development timeline: preclinical animal studies and Phase 1 and Phase 2a trials are described as complete, with a U.S.-based clinical trial estimated to start in Q1 2027 and a Phase 3 trial estimated to start in Q1 2028, subject to funding, technical risks and regulatory approvals. The company states it needs additional capital to continue implementing its business strategy and warns that failure to obtain sufficient funding could delay or prevent these activities. It also cites maintaining NYSE American listing compliance as a risk factor.

Risks

• Going concern and need for capital — The company's auditor included an explanatory paragraph expressing substantial doubt about its ability to continue as a going concern, and the 10-K states additional capital will be required beyond the current planning horizon.
• No revenue and recurring losses — Oragenics reports no meaningful revenues and has incurred significant operating losses since inception, with net losses of $984.2M in 2025 and $1.06B in 2024 as reported.
• Clinical and regulatory timing risk — The stated development timeline for ONP-002, including an estimated Q1 2027 U.S. trial start and Q1 2028 Phase 3 start, is an estimate subject to change based on funding, technical risks and regulatory approvals.
• Listing compliance — The company cites ability to maintain compliance with NYSE American continued listing requirements as a risk factor, and a 2026-08-28 8-K reports a delisting notice or listing-rule failure.

Outlook

Management's stated plan is to continue developing ONP-002 for mTBI, with an estimated U.S.-based clinical trial start in Q1 2027 and an estimated Phase 3 start in Q1 2028. The company states these timelines assume it obtains sufficient funding in the near term and thereafter. It also cautions that failure to timely obtain sufficient funding, or unexpected developments, could delay or prevent these events.